Evolution of Precision Oncology, Personalized Medicine, and Molecular Tumor Boards

被引：2

作者：

Fujiwara, Yu ^{[1
]}

Kato, Shumei ^{[2
,3
]}

Kurzrock, Razelle ^{[4
,5
,6
,7
]}

机构：

[1] Roswell Pk Comprehens Canc Ctr, Dept Med, Elm & Carlton St, Buffalo, NY 14263 USA

[2] Univ Calif San Diego, Moores Canc Ctr, Ctr Personalized Canc Therapy, 3855 Hlth Sci Dr, La Jolla, CA 92093 USA

[3] Univ Calif San Diego, Moores Canc Ctr, Dept Med, Div Hematol & Oncol, La Jolla, CA USA

[4] Med Coll Wisconsin, Genom Sci & Precis Med Ctr, Froedtert & Med Coll Wisconsin Canc Ctr, 9200 West Wisconsin Ave, Milwaukee, WI 53226 USA

[5] John A Mellowes Ctr Genom Sci & Precis Med, 9200 West Wisconsin Ave, Milwaukee, WI 53226 USA

[6] WIN Consortium, Paris, France

[7] Univ Nebraska, Lincoln, NE USA

来源：

SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA | 2024年 / 33卷 / 02期

关键词：

Histology-agnostic; Personalized medicine; Personalized oncology; Precision medicine; Tumor-agnostic; CELL LUNG-CANCER; DABRAFENIB PLUS TRAMETINIB; METASTATIC BREAST-CANCER; POSITIVE SOLID TUMORS; PHASE-II; COMBINATION THERAPY; OPEN-LABEL; TRIAL; PEMBROLIZUMAB; CHEMOTHERAPY;

D O I：

10.1016/j.soc.2023.12.004

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

With multiple molecular targeted therapies available for patients with cancer that correspond to a specific genetic alteration, the selection of the best treatment through discussion is essential to ensure therapeutic efficacy. MTBs play a key role in this decision -making process to deliver personalized medicine to patients with cancer in a multidisciplinary manner. Historically, personalized medicine has been offered to patients with advanced cancer, but the incorporation of molecular targeted therapies and immunotherapy into the perioperative setting requires clinicians, including surgeons, to understand the role of the MTB. Evidence is accumulating to support the feasibility and survival benefit in patients treated with the matched therapy proposed by the MTB, and the MTB will continue to play an integral role in incorporating the growing body of evidence of cancer therapy to provide personalized treatment for each patient with cancer.

引用

页码：197 / 216

页数：20

共 91 条

[81] Pan-Cancer Efficacy of Vemurafenib in BRAFV600-Mutant Non-Melanoma Cancers [J].

Subbiah, Vivek ;

Puzanov, Igor ;

Blay, Jean-Yves ;

Chau, Ian ;

Lockhart, A. Craig ;

Raje, Noopur S. ;

Wolf, Juergen ;

Baselga, Jose ;

Meric-Bernstam, Funda ;

Roszik, Jason ;

Diamond, Eli L. ;

Riely, Gregory J. ;

Sherman, Eric J. ;

Riehl, Todd ;

Pitcher, Bethany ;

Hyman, David M. .

CANCER DISCOVERY, 2020, 10 (05) :657-663

[82] Review of precision cancer medicine: Evolution of the treatment paradigm [J].

Tsimberidou, Apostolia M. ;

Fountzilas, Elena ;

Nikanjam, Mina ;

Kurzrock, Razelle .

CANCER TREATMENT REVIEWS, 2020, 86

[83] Precision medicine: preliminary results from the Initiative for Molecular Profiling and Advanced Cancer Therapy 2 (IMPACT2) study [J].

Tsimberidou, Apostolia Maria ;

Hong, David S. ;

Fu, Siqing ;

Karp, Daniel D. ;

Piha-Paul, Sarina ;

Kies, Merrill S. ;

Ravi, Vinod ;

Subbiah, Vivek ;

Patel, Sunil M. ;

Tu, Shi-Ming ;

Janku, Filip ;

Heymach, John ;

Johnson, Amber ;

Cartwright, Carrie ;

Zhao, Li ;

Zhang, Jianhua ;

Berry, Donald A. ;

Vining, David J. ;

Futreal, Andrew ;

Miller, Vincent A. ;

Meric-Bernstam, Funda .

NPJ PRECISION ONCOLOGY, 2021, 5 (01)

[84] Long-term overall survival and prognostic score predicting survival: the IMPACT study in precision medicine [J].

Tsimberidou, Apostolia-Maria ;

Hong, David S. ;

Wheler, Jennifer J. ;

Falchook, Gerald S. ;

Janku, Filip ;

Naing, Aung ;

Fu, Siqing ;

Piha-Paul, Sarina ;

Cartwright, Carrie ;

Broaddus, Russell R. ;

Gonzalez, Graciela M. Nogueras ;

Hwu, Patrick ;

Kurzrock, Razelle .

JOURNAL OF HEMATOLOGY & ONCOLOGY, 2019, 12 (01)

[85] Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center Initiative [J].

Tsimberidou, Apostolia-Maria ;

Iskander, Nancy G. ;

Hong, David S. ;

Wheler, Jennifer J. ;

Falchook, Gerald S. ;

Fu, Siqing ;

Piha-Paul, Sarina ;

Naing, Aung ;

Janku, Filip ;

Luthra, Rajyalakshmi ;

Ye, Yang ;

Wen, Sijin ;

Berry, Donald ;

Kurzrock, Razelle .

CLINICAL CANCER RESEARCH, 2012, 18 (22) :6373-6383

[86] Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC [J].

Tsuboi, Masahiro ;

Herbst, Roy S. ;

John, Thomas ;

Kato, Terufumi ;

Majem, Margarita ;

Grohe, Christian ;

Wang, Jie ;

Goldman, Jonathan W. ;

Lu, Shun ;

Su, Wu-Chou ;

de Marinis, Filippo ;

Shepherd, Frances A. ;

Lee, Ki Hyeong ;

Le, Nhieu Thi ;

Dechaphunkul, Arunee ;

Kowalski, Dariusz ;

Poole, Lynne ;

Bolanos, Ana ;

Rukazenkov, Yuri ;

Wu, Yi-Long .

NEW ENGLAND JOURNAL OF MEDICINE, 2023, 389 (02) :137-147

[87] Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer [J].

Tutt, Andrew N. J. ;

Garber, Judy E. ;

Kaufman, Bella ;

Viale, Giuseppe ;

Fumagalli, Debora ;

Rastogi, Priya ;

Gelber, Richard D. ;

de Azambuja, Evandro ;

Fielding, Anitra ;

Balmana, Judith ;

Domchek, Susan M. ;

Gelmon, Karen A. ;

Hollingsworth, Simon J. ;

Korde, Larissa A. ;

Linderholm, Barbro ;

Bandos, Hanna ;

Senkus, E. ;

Suga, Jennifer M. ;

Shao, Z. ;

Pippas, Andrew W. ;

Nowecki, Zbigniew ;

Huzarski, Tomasz ;

Ganz, Patricia A. ;

Lucas, Peter C. ;

Baker, Nigel ;

Loibl, Sibylle ;

McConnell, Robin ;

Piccart, Martine ;

Schmutzler, Rita ;

Steger, Guenther G. ;

Costantino, Joseph P. ;

Arahmani, Amal ;

Wolmark, Norman ;

McFadden, Eleanor ;

Karantza, Vassiliki ;

Lakhani, Sunil R. ;

Yothers, Greg ;

Campbell, Christine ;

Geyer, Charles E. .

NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (25) :2394-2405

[88] Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer [J].

von Minckwitz, G. ;

Huang, C. -S. ;

Mano, M. S. ;

Loibl, S. ;

Mamounas, E. P. ;

Untch, M. ;

Wolmark, N. ;

Rastogi, P. ;

Schneeweiss, A. ;

Redondo, A. ;

Fischer, H. H. ;

Jacot, W. ;

Conlin, A. K. ;

Arce-Salinas, C. ;

Wapnir, I. L. ;

Jackisch, C. ;

DiGiovanna, M. P. ;

Fasching, P. A. ;

Crown, J. P. ;

Wuelfing, P. ;

Shao, Z. ;

Caremoli, E. Rota ;

Wu, H. ;

Lam, L. H. ;

Tesarowski, D. ;

Smitt, M. ;

Douthwaite, H. ;

Singel, S. M. ;

Geyer, C. E., Jr. .

NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (07) :617-628

[89] Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer [J].

von Minckwitz, Gunter ;

Procter, Marion ;

de Azambuja, Evandro ;

Zardavas, Dimitrios ;

Benyunes, Mark ;

Viale, Giuseppe ;

Suter, Thomas ;

Arahmani, Amal ;

Rouchet, Nathalie ;

Clark, Emma ;

Knott, Adam ;

Lang, Istvan ;

Levy, Christelle ;

Yardley, Denise A. ;

Bines, Jose ;

Gelber, Richard D. ;

Piccart, Martine ;

Baselga, Jose .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (02) :122-131

[90] Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial [J].

Wen, Patrick Y. ;

Stein, Alexander ;

van den Bent, Martin ;

De Greve, Jacques ;

Wick, Antje ;

de Vos, Filip Y. F. L. ;

von Bubnoff, Nikolas ;

van Linde, Myra E. ;

Lai, Albert ;

Prager, Gerald W. ;

Campone, Mario ;

Fasolo, Angelica ;

Lopez-Martin, Jose A. ;

Kim, Tae Min ;

Mason, Warren P. ;

Hofheinz, Ralf-Dieter ;

Blay, Jean-Yves ;

Cho, Daniel C. ;

Gazzah, Anas ;

Pouessel, Damien ;

Yachnin, Jeffrey ;

Boran, Aislyn ;

Burgess, Paul ;

Ilankumaran, Palanichamy ;

Gasal, Eduard ;

Subbiah, Vivek .

LANCET ONCOLOGY, 2022, 23 (01) :53-64

← 1 2 3 4 5 6 7 8 9 10 →